Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Invested Capital (2018 - 2025)

Historic Invested Capital for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $224.6 million.

  • Arcturus Therapeutics Holdings' Invested Capital fell 1424.66% to $224.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $224.6 million, marking a year-over-year decrease of 1424.66%. This contributed to the annual value of $241.0 million for FY2024, which is 1347.69% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Invested Capital of $224.6 million as of Q3 2025, which was down 1424.66% from $231.1 million recorded in Q2 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Invested Capital peaked at $355.7 million during Q1 2021, and registered a low of $173.4 million during Q3 2022.
  • Its 5-year average for Invested Capital is $263.8 million, with a median of $264.0 million in 2024.
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 199475.92% in 2021, then plummeted by 4124.54% in 2022.
  • Arcturus Therapeutics Holdings' Invested Capital (Quarter) stood at $276.1 million in 2021, then increased by 16.15% to $320.7 million in 2022, then fell by 13.16% to $278.5 million in 2023, then decreased by 13.48% to $241.0 million in 2024, then decreased by 6.81% to $224.6 million in 2025.
  • Its Invested Capital was $224.6 million in Q3 2025, compared to $231.1 million in Q2 2025 and $233.8 million in Q1 2025.